1. Home
  2. KOS vs CDNA Comparison

KOS vs CDNA Comparison

Compare KOS & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kosmos Energy Ltd. (DE)

KOS

Kosmos Energy Ltd. (DE)

HOLD

Current Price

$2.47

Market Cap

1.8B

Sector

Energy

ML Signal

HOLD

Logo CareDx Inc.

CDNA

CareDx Inc.

HOLD

Current Price

$28.55

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KOS
CDNA
Founded
2003
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Medical Specialities
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.5B
IPO Year
2011
2007

Fundamental Metrics

Financial Performance
Metric
KOS
CDNA
Price
$2.47
$28.55
Analyst Decision
Hold
Buy
Analyst Count
6
6
Target Price
$1.91
$28.00
AVG Volume (30 Days)
14.3M
940.6K
Earning Date
05-05-2026
04-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.05
Revenue
$1,288,352,000.00
$48,324,000.00
Revenue This Year
$27.11
$16.01
Revenue Next Year
N/A
$11.31
P/E Ratio
N/A
$570.20
Revenue Growth
N/A
18.93
52 Week Low
$0.84
$10.96
52 Week High
$3.34
$30.00

Technical Indicators

Market Signals
Indicator
KOS
CDNA
Relative Strength Index (RSI) 52.84 61.83
Support Level $2.33 $16.63
Resistance Level $3.09 $30.00
Average True Range (ATR) 0.16 1.26
MACD 0.04 -0.10
Stochastic Oscillator 97.92 73.64

Price Performance

Historical Comparison
KOS
CDNA

About KOS Kosmos Energy Ltd. (DE)

Kosmos Energy Ltd is a deepwater exploration and production company focused on meeting the world's growing demand for energy. It has diversified oil and gas production from assets offshore Ghana, Equatorial Guinea, Mauritania, Senegal and the Gulf of America. The Company had operations in four geographic reporting segments: Ghana, Equatorial Guinea, Mauritania/Senegal and the Gulf of America. The majority of revenue is derived from the Ghana segment.

About CDNA CareDx Inc.

CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.

Share on Social Networks: